On the other hand, a study by Cheng et al. demonstrated that serum from COVID-19 patients showed neutralizing capacity against DENV infection in vitro and that this activity was blocked in the presence of the receptor-binding domain (RBD) of the Spike 1 (S1) protein, but not of the SARS-CoV-2 nucleocapsid protein, suggesting cross-reactivity of S1-RBD antibodies that may be involved in the inhibition of DENV infection in COVID-19 patients [15]. This evidence concerns the gene PSMD1 and COVID-19.